Loading company…
Simmunome uses AI and disease models to support drug development and clinical research.
Simmunome develops in silico disease models for pharmaceutical companies and academic labs, with a focus on oncology, neurodegenerative diseases, and regenerative medicine. Its models use multi-omic data and generative AI to examine disease mechanisms, target populations, and safety profiles. Founded in 2017, the company is based in Montreal, Canada. In September 2023, it raised CAD 2 million in pre-seed funding co-led by Investissement Québec and Theodorus, with ACET Capital, BKR Capital, Front Row Ventures, and Sandpiper Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in